 The FDA has approved Impel NeuroPharma Incs NASDAQ: IMPL Trudhesa dihydroergotamine mesylate nasal spray for the acute treatment of migraine with or without aura in adults. Using Impels Precision Olfactory Delivery technology, Trudhesa gently delivers dihydroergotamine mesylate to the bloodstream through the vascular-rich upper nasal space. 